Compounds > dibenzyl diselenide
Page last updated: 2024-12-07

dibenzyl diselenide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibenzyl diselenide is an organoselenium compound with the formula (PhCH2Se)2. It is a yellow solid that is soluble in organic solvents. Dibenzyl diselenide is a synthetic compound with the molecular formula C14H14Se2. It is a key precursor for other selenium compounds, particularly those used in biological applications. Dibenzyl diselenide is considered to be a potential antioxidant and has shown promise in protecting against oxidative stress. Its properties make it an interesting subject for investigating the therapeutic potential of selenium compounds. For instance, research is ongoing to evaluate its potential benefits in the context of cardiovascular health and neurodegenerative diseases.'

dibenzyl diselenide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID95955
CHEMBL ID1806807
MeSH IDM0197952

Synonyms (31)

Synonym
dibenzyl diselenide
nsc44641
diselenide, bis(phenylmethyl)
nsc-44641
nsc49764
benzyl diselenide
dibenzyldiselenium
nsc-49764
dibenzyldiselane
diselane, bis(phenylmethyl)-
inchi=1/c14h14se2/c1-3-7-13(8-4-1)11-15-16-12-14-9-5-2-6-10-14/h1-10h,11-12h
1482-82-2
(benzyldiselanyl)methylbenzene
D2717
bisbenzyldiselenide
CHEMBL1806807
nsc 44641
nsc 49764
AKOS005192801
FT-0624651
1,2-dibenzyldiselane
1,2-dibenzyldiselane #
AC-31138
mfcd00004767
DTXSID70163934
4-(3-chloro-phenyl)-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinoline-8-carboxylicacid
BCP10705
STL444020
H10814
CS-W011906
SY033181
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID608452Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 amastigotes after 24 hrs by microscopy2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608446Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 amastigotes expressing GFP infected in human THP1 cells assessed as parasite infected cells after 48 hrs by flow cytometry (Rvb = 35%)2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608355Permeability across human Caco2 cells2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608453Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 promastigotes after 24 hrs by microscopy2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608456Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 promastigotes assessed as growth inhibition at 12.5 uM after 24 hrs2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608455Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 promastigotes assessed as growth inhibition at 25 uM after 24 hrs2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608451Selectivity ratio, ratio of IC50 for human Jurkat cells to IC50 for Leishmania infantum MCAN/ES/89/IPZ229/1/89 amastigotes2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608356Human intestinal absorption in human2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608457Antileishmanial activity against Leishmania infantum MCAN/ES/89/IPZ229/1/89 promastigotes assessed as growth inhibition at 6.25 uM after 24 hrs2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608354Cytotoxicity against human Jurkat cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608454Cytotoxicity against human THP1 cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
AID608450Selectivity ratio, ratio of IC50 for human THP1 cells to IC50 for Leishmania infantum MCAN/ES/89/IPZ229/1/89 amastigotes2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.01 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
edelfosine
edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.		2.0610glycerophosphocholine
ethoxyresorufin
ethoxyresorufin: structure		1.9910phenoxazine
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.0610phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
1,4-phenylenebis(methylene)selenocyanate
1,4-phenylenebis(methylene)selenocyanate: structure given in first source; inhibits DMBA-induced carcinogenesis by inhibiting DMBA-DNA adduct formation		1.9910
2-anthramine
2-anthramine: structure		1.9910anthracenamine
sodium selenite
disodium selenite : An inorganic sodium salt composed of sodium and selenite ions in a 2:1 ratio.		1.9910inorganic sodium salt;
selenite salt		nutraceutical
benzyl selenocyanate
benzyl selenocyanate: prevents colon carcinogenesis		2.4220
cyanates
Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Black Fever
[description not available]		02.0610
Benign Neoplasms
[description not available]		02.0610
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610